Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors
Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer
Gleevec Approval Sets Record For FDA Review: 73 Days
Advances Found In Treatment Of Aerodigestive Cancers
Silicone Implants Not Linked To Increased Risk Of Death
B-14 Trial: No Advantage To 10 Years Of Tamoxifen
NCI-Approved Clinical Trials Listed For April 2001
Trending Stories
- Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care - Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park - Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed